Azevan Pharmaceuticals is a private, clinical-stage company pioneering a novel approach to treating CNS disorders by selectively targeting the vasopressin 1a receptor (V1aR). Its lead asset, SRX246, has completed Phase 2 trials in Huntington's disease-related aggression and Intermittent Explosive Disorder, showing clinical benefit and excellent tolerability, and is poised to enter a Phase 2 trial in Fragile X Syndrome. The company's strategy targets high-unmet-need, often rare, neuropsychiatric and neurodevelopmental indications as a pathway to potentially larger markets in TBI and neurodegenerative diseases. Azevan's work is supported by significant non-dilutive funding from U.S. government agencies.
Discovery and development of selective, orally bioavailable small molecule antagonists of the vasopressin 1a receptor (V1aR) for modulating stress, fear, and aggression pathways in the central nervous system.
Funding History
2
Total raised:$3.7M
Grant$2.2MNational Institutes of Health
Grant$1.5MNational Institutes of Health
Opportunities
The primary opportunity lies in addressing massive unmet needs across multiple CNS domains: no approved treatments for aggression in Huntington's disease or anxiety/aggression in Fragile X Syndrome, and no disease-modifying drugs for traumatic brain injury.
Success in these targeted, high-unmet-need areas provides a clear regulatory pathway and could validate the platform for expansion into larger indications like Alzheimer's disease and broader autism spectrum disorder.
Risk Factors
Key risks include the inherent uncertainty of clinical development, particularly in measuring behavioral endpoints in CNS trials, and the challenge of transitioning from Phase 2 proof-of-concept to pivotal studies.
As a private, grant-funded company, there is significant funding and operational risk, with future development contingent on securing additional capital or strategic partnerships.
Competitive Landscape
Competition is fragmented by indication. In Huntington's disease aggression, competitors include off-label use of antipsychotics and mood stabilizers. In Fragile X and ASD, numerous companies are investigating various mechanisms (e.g., mGluR5, GABA), but none are V1aR antagonists. In TBI, the competitive field is crowded with failed historical attempts, but Azevan's specific, mechanism-based approach targeting the acute injury cascade via V1aR is novel and differentiated.
